Vigeo Therapeutics Inc is a clinical-stage biopharmaceutical company based in Boston, MA, dedicated to developing innovative therapeutics for various types of cancer. Their approach involves reprogramming the tumor immune microenvironment (TIME) to enhance cancer treatment outcomes. By activating thrombospondin-1 (Tsp-1), a natural anti-tumorigenic protein, Vigeo aims to target cancer cells and inhibit metastasis through CD36 and CD47 pathways.
Vigeo Therapeutics is currently conducting clinical trials for VT1021, a peptide therapeutic agent, in patients with pancreatic, ovarian, triple negative breast cancers, glioblastoma, and tumors with high levels of CD36. Their commitment to advancing cancer treatment is evident through their recent clinical updates and presentations, showcasing their progress in the field of oncology.
Generated from the website